Filgrastim - Biologic Drug Details

Summary for filgrastim

Tradenames:	1
High Confidence Patents:	5
Applicants:	4
BLAs:	4
Suppliers: see list	4
Recent Clinical Trials:	See clinical trials for filgrastim

Recent Clinical Trials for filgrastim

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Takeda	PHASE2
City of Hope Medical Center	PHASE1
Diakonos Oncology Corporation	PHASE1

See all filgrastim clinical trials

Pharmacology for filgrastim

Physiological Effect	Increased Myeloid Cell Production
Established Pharmacologic Class	Leukocyte Growth Factor
Chemical Structure	Granulocyte Colony-Stimulating Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for filgrastim Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for filgrastim Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353	4,810,643	2006-03-03	DrugPatentWatch analysis and company disclosures
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353	4,999,291	2009-03-06	DrugPatentWatch analysis and company disclosures
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353	5,528,823	2015-06-01	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for filgrastim Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353	10,016,338	2036-12-20	Patent claims search
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353	10,039,808	2035-10-19	Patent claims search
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353	10,053,498	2035-11-20	Patent claims search

International Patents for filgrastim

Country	Patent Number	Estimated Expiration
Japan	H06181791
Germany	69318273
China	1020924

Supplementary Protection Certificates for filgrastim

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
92359	Luxembourg		PRODUCT NAME: LIPEGFILGRASTIM
CA 2014 00003	Denmark		PRODUCT NAME: LIPEGFILGRASTIM, HERUNDER METHOXYPOLYETHYLENGLYCOL KONJUGAT; REG. NO/DATE: EU/1/13/856 20130725
92358	Luxembourg		PRODUCT NAME: LIPEGFILGRASTIM

Filgrastim Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

Filgrastim is a well-established biologic in oncology and supportive care that has traded as a mature, patent-exposed asset. Market growth has largely shifted from “originator volume” to a mix of (1) biosimilar-led price compression, (2) life-cycle extensions around longer-acting or device-led formulations, and (3) contract-driven distribution in hospital and integrated delivery networks. The financial trajectory for filgrastim products has therefore been defined less by category expansion and more by margin pressure, channel mix, and the shift toward pegfilgrastim and other G-CSF delivery strategies.

What is filgrastim’s market structure and demand base?

Demand pools

Filgrastim (G-CSF) is used primarily for:

• Chemotherapy-induced neutropenia (CIN) prevention and treatment
• Mobilization of peripheral blood stem cells (PBSC) for autologous transplantation

These use cases are recurring across major oncology regimens and are influenced by:

• Cancer incidence and regimen mix (higher-intensity chemotherapy drives higher supportive care intensity)
• Guideline behavior (dose density, prophylaxis criteria, and institutional protocols)
• Access economics (biosimilar penetration, formulary status, and reimbursement policy)

Channel mechanics

Filgrastim’s commercial reality is shaped by the procurement structure of:

• Hospital purchasing (tendering and GPO contracting)
• Integrated delivery networks (standard-of-care and formulary decisions)
• Specialty pharmacy vs hospital buy-and-bill split (changes by region and payer)

This creates a market where originator brands usually lose share fastest once interchangeability/biosimilar coverage broadens and procurement thresholds favor the lowest net cost.

How has pricing and market share evolved under biosimilar competition?

The market is structurally prone to price compression

Filgrastim is an “expiring-blockbuster” pattern biologic where the originator’s financial trajectory typically shows:

1. Stable pricing early after launch
2. Share erosion around first biosimilar entries
3. Net price compression after multiple products secure coverage and expand into institutional formularies

This pattern is consistent with the broader biosimilar competitive mechanism in oncology supportive care, where buying behavior is highly price-sensitive after formulary inclusion.

Biosimilar availability is a key driver

Filgrastim’s market dynamics are anchored to whether biosimilar products are available, reimbursed, and distributed at scale in each geography. The U.S. and EU have supported multiple filgrastim biosimilar launches, and the commercial outcome is dominated by which products achieve:

• Broad formulary access
• Efficient procurement positioning through hospital contracts
• Competitive acquisition costs and payer coverage

The biologics regulatory framework that enables biosimilar approvals is the Biologics Price Competition and Innovation Act (BPCIA) in the U.S. [1]. In the EU, biosimilar authorizations follow the centralized EMA process under EU biosimilar regulation [2].

What role do life-cycle shifts play versus pegfilgrastim and other G-CSF strategies?

Pegfilgrastim competes on dosing convenience and workflow

Even when filgrastim remains indicated, clinicians and hospital pharmacies increasingly favor pegfilgrastim strategies because pegylation typically reduces injection frequency and improves operational workflow. This does not eliminate filgrastim demand, but it:

• Moves some prophylaxis patients to pegfilgrastim-based schedules
• Shifts formularies toward fewer dosing protocols
• Reduces total filgrastim addressable share growth

Longer-acting and delivery evolution impacts net share

Filgrastim product sets have also faced incremental category churn as newer delivery designs (including different dosing regimens and treatment workflows across G-CSFs) penetrate standard oncology supportive care pathways. The financial outcome is less about absolute market growth and more about share of supportive care episodes.

How do regulatory events and exclusivity windows shape filgrastim’s financial path?

U.S. biosimilar authorization framework

In the U.S., the path to biosimilar entry is governed by the BPCIA, which defines approval standards and incentives tied to exclusivity and reference product protections [1]. Once exclusivity and patent fences clear, multiple filgrastim biosimilars can scale, accelerating net price declines.

EU centralized biosimilar approvals

In the EU, EMA centralized authorization allows biosimilar approvals that can expand access quickly after regulatory clearance [2]. That matters for filgrastim because many hospital systems standardize G-CSF purchasing after biosimilars demonstrate regulatory equivalence.

What is the financial trajectory of the filgrastim category in practice?

Baseline pattern: revenue stabilizes, then declines in real terms after biosimilar penetration

A typical filgrastim financial trajectory after widespread biosimilar availability looks like this:

• Originator revenue: peaks, then declines as share erodes to biosimilars
• Category revenue: may remain stable or grow modestly, but growth is captured by biosimilars and competitors at lower prices
• Margins: compress across brands, especially in institutional procurement

Why “category value” and “product revenue” diverge

Even if oncology supportive care episodes increase, the value captured by each product declines because:

• Net prices fall after formulary switching
• Biosimilars often displace originator inventory
• Procurement contracts prioritize lowest net cost for equivalent outcomes

Competitive set affects revenue more than clinical outcomes

Since clinical outcomes under biosimilar and reference products are highly comparable in approved indications, procurement decisions become the dominant revenue driver. The financial trajectory is therefore contract and tender dependent rather than differentiation driven.

What are the main market forces that still favor filgrastim demand?

Despite pricing pressure, filgrastim retains structural demand due to:

• Indication breadth across oncology supportive care
• Use in PBSC mobilization, where clinician and transplant center workflows can sustain demand
• Protocol-driven dosing where filgrastim fits certain regimen timing and patient-specific factors

This produces a resilient base, but one that is increasingly served at competitive acquisition prices.

Which business indicators matter most for investors and manufacturers?

Market and commercial metrics

Key indicators that determine whether a filgrastim product’s financial trajectory improves or deteriorates:

• Hospital formulary position (tier placement and switching frequency)
• Contract pricing and volume commitments (GPO and regional tenders)
• Share against pegfilgrastim strategies (conversion rates to alternate G-CSF workflows)
• Regional coverage and reimbursement depth (payer policy and procurement rules)
• Product access and logistics (stock availability in hospital channels)

Product portfolio actions that drive outcomes

Manufacturers typically respond to biosimilar competition by:

• Maintaining supply and distribution capacity to avoid lost tender bids
• Managing contract pricing and service terms to preserve volume
• Targeting procurement segments where the net cost delta is less punitive

How does global policy environment affect filgrastim economics?

U.S. and EU frameworks underpin access and competition

The U.S. biosimilar approval and exclusivity regime shapes the speed and aggressiveness of competition [1]. The EU centralized biosimilar process enables a parallel trajectory in Europe through systematic regulatory authorization [2].

In both regions, procurement incentives reward biosimilar adoption, which directly impacts:

• Net selling prices
• Revenue mix
• Operating margin

Where does the money likely go next in G-CSF supportive care?

Shift toward pegfilgrastim convenience and protocol adoption

As supportive care protocols optimize dosing schedules and reduce injection frequency, some patient populations move away from daily filgrastim. That compresses filgrastim’s growth rate and biases revenue toward:

• Patients who require filgrastim specifically due to protocol timing
• Settings where filgrastim is operationally preferred through contracting

Biosimilar consolidation and portfolio optimization

Expect the competitive landscape to continue to reward firms that secure broad access at scale. Over time, this tends to produce:

• Fewer winners with sustained tender positions
• A competitive margin ceiling for all filgrastim products

Key Takeaways

• Filgrastim is anchored to recurring oncology supportive care and PBSC mobilization, but category economics are dominated by biosimilar-driven net price compression and hospital contracting.
• The financial trajectory typically follows an originator revenue decline after biosimilar scale, while category value may stabilize or grow modestly with lower captured prices.
• Pegfilgrastim and other G-CSF delivery strategies limit filgrastim growth by shifting some prophylaxis episodes toward less frequent dosing workflows.
• Regulatory frameworks in the U.S. (BPCIA) and EU (EMA centralized biosimilar authorizations) set the pace of competition and therefore the slope of pricing pressure [1,2].

FAQs

1) What is the biggest driver of filgrastim revenue changes in mature markets?
Biosimilar penetration and hospital contract pricing, which determine net selling prices and formulary share.

2) Does filgrastim have demand beyond chemotherapy-induced neutropenia?
Yes. Filgrastim also supports peripheral blood stem cell mobilization in autologous transplantation workflows.

3) Why can filgrastim revenue decline even if oncology volumes rise?
Higher supportive care volume can be offset by lower net prices and share transfer to biosimilars after formulary switching.

4) How does pegfilgrastim affect filgrastim’s commercial outlook?
Pegfilgrastim can capture a portion of prophylaxis patients due to dosing convenience and protocol adoption, limiting filgrastim’s share growth.

5) What regulatory mechanism most affects biosimilar entry timing in the U.S.?
The BPCIA framework, which governs biosimilar approval pathways and exclusivity dynamics for reference products [1].

---

References

[1] U.S. Food and Drug Administration. (n.d.). Biosimilars: Overview. FDA. https://www.fda.gov/drugs/biosimilars

[2] European Medicines Agency. (n.d.). Biosimilar medicines. EMA. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/biosimilar-medicines